With 3.67 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.01 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $17.14 whereas the lowest price it dropped to was $14.62. The 52-week range on DFTX shows that it touched its highest point at $15.88 and its lowest point at $4.70 during that stretch. It currently has a 1-year price target of $28.67. Beta for the stock currently stands at 2.63.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DFTX was up-trending over the past week, with a rise of 20.89%, but this was up by 38.33% over a month. Three-month performance surged to 22.93% while six-month performance rose 68.64%. The stock gained 25.32% in the past year, while it has gained 157.76% so far this year. A look at the trailing 12-month EPS for DFTX yields -1.97 with Next year EPS estimates of -1.78. For the next quarter, that number is -0.50. This implies an EPS growth rate of -29.53% for this year and 10.69% for next year. EPS is expected to decline by -1.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 12.11%.
Float and Shares Shorts:
At present, 76.77 million DFTX shares are outstanding with a float of 73.44 million shares on hand for trading. On 2025-12-31, short shares totaled 15.05 million, which was 1528.0 higher than short shares on 1764288000. In addition to Mr. Robert Barrow as the firm’s CEO & Director, Mr. Mark R. Sullivan J.D. serves as its Chief Legal Officer & Corporate Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, DFTX reported revenue of $0.0 and operating income of -$45669000.0. The EBITDA in the recently reported quarter was -$43407000.0 and diluted EPS was -$0.78.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With DFTX analysts setting a high price target of 61.0 and a low target of 16.0, the average target price over the next 12 months is 28.66667. Based on these targets, DFTX could surge 263.53% to reach the target high and fall by -4.65% to reach the target low. Reaching the average price target will result in a growth of 70.84% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. The surprise factor in the prior quarter was -$0.36. Based on analyst estimates, the high estimate for the next quarter is -$0.43 and the low estimate is -$0.49. The average estimate for the next quarter is thus -$0.46.
